Form 4: Eton Pharma CCO Sells Shares for Tax Withholding

Eton Pharmaceuticals' Chief Commercial Officer, Ipek Erdogan-Trinkaus, disposed of 85 shares of common stock to cover tax obligations related to restricted stock unit vesting.

Summary

• Ipek Erdogan-Trinkaus, Chief Commercial Officer of Eton Pharmaceuticals, Inc. (ETON), reported a transaction on December 12, 2025.
• 85 shares of common stock were disposed of by the Issuer to satisfy applicable withholding taxes upon the vesting of restricted stock units.
• The shares were valued at a weighted average sales price of $16.90, with trades ranging from $16.90 to $16.91 per share.
• Following this transaction, Erdogan-Trinkaus beneficially owns 2,403 shares of common stock directly.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction for tax withholding purposes, which is a neutral event and does not indicate positive or negative sentiment regarding the company's performance or outlook.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Industry Context

This Form 4 filing details an insider transaction related to compensation and tax obligations, which is a routine event for publicly traded companies and does not provide broader industry context or trends.

Stakeholder Impact

• The disposition of 85 shares for tax withholding is a minor, routine event with negligible impact on shareholders, employees, customers, suppliers, or creditors.

Key Dates

Keywords

Eton Pharmaceuticals, ETON, Form 4, Insider Transaction, Stock Disposition, Restricted Stock Units, Tax Withholding, Chief Commercial Officer